On this page
Deep Dive — Evidence Details
Bottom Line
- ▸Corticosteroids, NSAIDs, and low-dose colchicine are all high-strength, first-line options for acute gout pain relief.
- ▸Naproxen and low-dose colchicine provide equivalent pain reduction, but naproxen is associated with significantly fewer gastrointestinal side effects.
- ▸Oral prednisolone (30-35 mg/day) offers similar efficacy to NSAIDs with a lower risk of nausea and vomiting.
First-line treatment for acute gout consists of , nonsteroidal anti-inflammatory drugs ( ), or [1]A1c[10]A1c. High-strength evidence confirms all three classes effectively reduce pain [1]A1c. The American College of Physicians (ACP) recommends (e.g., ), (e.g., , ), or low-dose as initial options (Grade: strong recommendation, high-quality evidence) [10]A1c.
Comparative Efficacy and Safety
-to-head trials demonstrate no significant difference in pain reduction between these agents [15]B2b[18]A1a[19]A1a. In a pragmatic trial, (750 mg then 250 mg every 8 hours for 7 days) and low-dose (500 mcg three times daily for 4 days) showed no significant difference in average pain-change scores (mean difference -0.18; 95% CI -0.53 to 0.17) [15]B2b. However, was associated with fewer side effects; increased the risk of diarrhea (45.9% vs 20.0%; OR 3.31) and headache (OR 1.92) [15]B2b.
(e.g., oral 30-35 mg/day) provide comparable pain relief to but may have a more favorable safety profile regarding symptoms, reducing risks of indigestion (RR 0.50), nausea (RR 0.25), and vomiting (RR 0.11) [18]A1a[19]A1a. For patients where conventional therapies are unsuitable, (100-200 mg/day for 5 days) is an effective alternative, showing non-inferiority to standard care [4]A1b[27]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| First-line Agent | preferred due to fewer side effects than colchicine [15]B2b. | , , and are equally first-line [1]A1c[10]A1c. | High | Choice depends on patient comorbidities and contraindications. |
| Colchicine Dosing | Low-dose is preferred for better tolerability [1]A1c[10]A1c. | High-dose was historically used but is no longer recommended [1]A1c. | Moderate | Low-dose is as effective with fewer GI adverse events. |
Pearl: , , and low-dose are equally effective for acute pain; select based on safety profiles, as carry lower gastrointestinal risk than , and are better tolerated than [15]B2b[19]A1a. (High, multiple RCTs and systematic reviews).
| Adverse Event | Colchicine (500 mcg tid) | Naproxen (250 mg tid) | Odds Ratio (95% CI) |
|---|---|---|---|
| Diarrhea | 45.9% | 20.0% | 3.31 (2.01-5.44) |
| Headache | 20.5% | 10.7% | 1.92 (1.03-3.55) |
| Constipation | 4.8% | 19.3% | 0.24 (0.11-0.54) |
Evolution of Treatment
- ▸High-dose colchicine has been replaced by low-dose regimens (0.5-1.2 mg) to avoid universal gastrointestinal toxicity.
- ▸Oral prednisolone (35 mg) is clinically equivalent to naproxen (1000 mg/day) for acute pain relief but carries lower risks of gastrointestinal distress.
- ▸Prophylaxis with low-dose colchicine during ULT initiation reduces flare frequency but its long-term cost-effectiveness remains contested.
The has transitioned from high-dose toxic regimens to evidence-based strategies utilizing low-dose , , and systemic . Historically, high-dose colchicine was the standard of care, but it was largely abandoned after trials demonstrated that the entire treatment group developed toxicity, including severe distress [32]B2a. Modern evidence confirms that low-dose colchicine is as effective as high-dose regimens while causing significantly fewer adverse events [1]A1c[10]A1c.
Pivotal Comparisons and Equivalence
-to-head trials have established therapeutic equivalence between the three primary drug classes. A landmark double-blind trial in 2008 demonstrated that oral (35 mg daily) and (500 mg twice daily) for 5 days were equally effective for monoarticular gout, with a pain reduction difference of only 1.3 mm on a 100 mm visual analogue scale (95% CI -9.8 to 7.1) [31]A1b. Subsequent meta-analyses of 817 patients confirmed no significant difference in pain scores at <7 days (SMD -0.09) or ≥7 days (SMD 0.32) between corticosteroids and NSAIDs [19]A1a. However, corticosteroids were associated with a lower risk of indigestion (RR 0.50), nausea (RR 0.25), and vomiting (RR 0.11) [19]A1a.
Evolution of Prophylaxis
The "start-low go-slow" approach to initiating urate-lowering therapy (ULT) emerged to mitigate mobilization flares. While early guidelines emphasized universal prophylaxis, recent data from a 12-month trial showed that placebo was not non-inferior to colchicine 0.5 mg daily during the first 6 months of titration (mean difference 0.25 flares/month, p=0.92 for non-inferiority) [2]A1b. Despite this efficacy, the CONTACT trial found no difference in pain intensity between naproxen and low-dose colchicine for acute flares, though naproxen had a superior safety profile regarding diarrhea (20.0% vs 45.9%; OR 3.31) [15]B2b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| First-line choice | ACP recommends corticosteroids, NSAIDs, or colchicine equally [10]A1c. | CONTACT trial supports NSAIDs as first-line in primary care due to fewer side effects [15]B2b. | Moderate | Choice depends on patient comorbidities and risk of GI/renal toxicity. |
| Prophylaxis Value | Colchicine prophylaxis is considered very cost-effective in some models [22]D5. | A 12-month trial found 6 months of colchicine prophylaxis unlikely to be cost-effective (INMB -$3,191) [14]A1b. | High | Long-term value of short-term prophylaxis is debated. |
Pearl: Therapeutic equivalence between low-dose colchicine, NSAIDs, and corticosteroids allows for selection based on comorbidity profiles, as no single class demonstrates superior pain relief in head-to-head trials [1]A1c[31]A1b.
| Intervention | Pain Reduction (VAS) | Adverse Event Profile | Evidence Level |
|---|---|---|---|
| ~46 mm reduction [31]A1b | Higher GI distress, nausea [15]B2b | 1b | |
| ~45 mm reduction [31]A1b | Lower GI risk, higher skin rash risk [18]A1a | 1b | |
| (Low-dose) | ES 0.87 [28]A1c | Diarrhea (45.9%) [15]B2b | 1c |
| Superior to triamcinolone [29]A1b | Infections, neutropenia [29]A1b | 1b |
Current Evidence and Standard
- ▸NSAIDs, corticosteroids, and low-dose colchicine are all strongly recommended as first-line options for acute gout flares with comparable efficacy in pain reduction.
- ▸Corticosteroids (e.g., prednisolone 30-35 mg/day) demonstrate a more favorable safety profile regarding gastrointestinal adverse events than NSAIDs or colchicine.
- ▸Anakinra is a non-inferior alternative for patients with contraindications to standard first-line therapies.
Standard pharmacological flares relies on three primary classes of anti-inflammatory agents: , nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids [1]A1c[10]A1c. The American College of Physicians (ACP) issues a strong recommendation for the use of any of these three classes to relieve pain in adults with acute gout [10]A1c. High-strength evidence from 28 trials confirms that all three interventions effectively reduce pain intensity [1]A1c.
Comparative Efficacy of First-Line Agents
-to-head trials generally demonstrate equivalent efficacy between these classes for pain reduction [1]A1c[15]B2b[19]A1a. In the multicenter CONTACT trial, (750 mg followed by 250 mg every 8 hours for 7 days) was compared to low-dose (500 mcg three times daily for 4 days) [15]B2b. No significant difference was found in average pain-change scores over 7 days (mean difference -0.18; 95% CI -0.53 to 0.17; p=0.32) [15]B2b. Similarly, meta-analyses comparing oral (30-35 mg/day) to NSAIDs (such as 500 mg/day or 50-100 mg/day) found comparable pain relief both in activity and at rest during the first 2-6 hours and over 4-6 days [18]A1a[19]A1a.
Safety and Tolerability Profiles
While efficacy is similar, safety profiles diverge significantly. Corticosteroids are associated with a lower risk of side effects compared to NSAIDs, including reduced risks of indigestion (RR 0.50, 95% CI 0.27-0.92), nausea (RR 0.25, 95% CI 0.11-0.54), and vomiting (RR 0.11) [19]A1a. Conversely, is associated with higher rates of diarrhea (45.9% vs 20.0%; OR 3.31) and headache (20.5% vs 10.7%; OR 1.92) compared to [15]B2b. Moderate-strength evidence supports the use of low-dose over high-dose regimens, as it provides similar efficacy with fewer gastrointestinal adverse events [1]A1c[10]A1c.
Interleukin-1 (IL-1) Inhibition
For patients in whom conventional therapies (NSAIDs and ) are unsuitable or contraindicated, IL-1 inhibitors serve as an effective alternative [4]A1b[9]B2a[27]D5. (100-200 mg/day for 5 days) has demonstrated non-inferiority to (40 mg single injection) for pain reduction, with mean declines in pain intensity of -41.2 and -39.4, respectively (p=0.688) [4]A1b[27]D5. may provide the highest pain reduction at day 2 compared to acetic acid derivative NSAIDs (mean difference -41.12 on a 0-100 scale), though it is typically reserved for refractory cases [9]B2a.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| First-line choice | ACP recommends any of the three classes (NSAID, Colchicine, Steroid) [10]A1c. | CONTACT trial suggests as first-line due to fewer side effects than [15]B2b. | Moderate | Clinical choice often depends on comorbidities (e.g., renal function, GI risk). |
| Prophylaxis duration | Moderate evidence suggests prophylaxis should exceed 8 weeks [1]A1c. | Recent trial found 6 months of prophylaxis not cost-effective over 12 months [14]A1b. | Low | Duration of prophylaxis remains individualized based on flare frequency. |
Pearl: NSAIDs, corticosteroids, and low-dose are equally effective for acute pain relief, but corticosteroids offer a superior gastrointestinal safety profile compared to NSAIDs and [15]B2b[19]A1a.
| Intervention | Comparator | Pain Relief (VAS/NRS) | Key Adverse Events |
|---|---|---|---|
| No significant difference (p=0.32) [15]B2b | Higher diarrhea/headache with colchicine [15]B2b | ||
| NSAIDs | Comparable relief at 2-6h and 4-6 days [18]A1a | Lower nausea/vomiting with steroids [19]A1a | |
| Non-inferior (p=0.688) [4]A1b | No unexpected safety findings [4]A1b[27]D5 |
Applicability and Caveats
- ▸Standard phase 3 gout trials often under-represent elderly, female, and multi-comorbid populations.
- ▸Colchicine prophylaxis is effective for preventing flares, including those triggered by vaccination, but carries risks in patients with severe CKD or interacting medications like statins.
- ▸Adherence to long-term therapy is suboptimal, with over 50% of patients discontinuing treatment within 5 years.
Clinical trial populations for gout therapeutics often fail to represent the comorbid complexity of the general population [44]B2b. Phase 3 trials for agents like , , and have historically over-represented men, younger individuals, and White participants while under-representing patients with , prior myocardial infarction, and diabetes [44]B2b. This discrepancy is critical because comorbidities and polypharmacy significantly alter the safety profile of first-line agents [37]B2b[46]D5.
Comorbidity and Drug Interactions
Renal and cardiovascular status are the primary determinants of treatment selection [46]D5[47]D5. While low-dose (1.5 mg on day 1, then 1 mg daily) is a standard of care, its use is complicated by frequent drug-drug interactions [37]B2b[50]B2b. Approximately 26% of patients initiating gout therapy are prescribed at least one interacting medication, most commonly (21%) [37]B2b. Although were not associated with increased adverse events in one large cohort, other interacting drugs and severe chronic kidney disease significantly increased the risk of diarrhea and myocardial infarction [37]B2b.
Cardiovascular Risk and Prophylaxis
The relationship between and cardiovascular outcomes in gout remains complex. While initiating guideline-concordant therapy (colchicine 0.6 mg once or twice daily plus a xanthine oxidase inhibitor) can improve brachial artery flow-mediated dilation by 58% (p = 0.03) and reduce hsCRP by 30% (p ≤ 0.03), these benefits are primarily seen in patients without established cardiovascular disease [43]D5. Conversely, a nationwide study found that higher cumulative doses of (≥180 cDDDs) were associated with an increased risk of atherosclerotic cardiovascular events (OR 1.21, 95% CI 1.09-1.35) in patients with newly diagnosed gout [40]B3b.
Adherence and Socioeconomic Factors
Real-world adherence to urate-lowering therapy (ULT) is poor, with non-persistence reaching 56.9% at 5 years [20]B2b. Factors influencing adherence and severity include:
- Socioeconomic Status: Lower individual-level education is associated with having ≥2 gout attacks per year (ORadj 0.54, 95% CI 0.36-0.81) [41]D5.
- Demographics: Females and younger patients have a higher risk of non-persistence [20]B2b.
- Clinical Inertia: Only 46.3% of patients with poorly controlled gout (defined as ≥2 attacks/year) are prescribed , and only 13.4% receive doses ≥300 mg [48]B2b.
Special Clinical Scenarios
- Vaccination: vaccination is associated with higher odds of gout flare within 3 months (adjusted OR 6.02, 95% CI 3.00-12.08) [38]D5. Prophylactic use was associated with a 47% lower likelihood of these post-vaccine flares [38]D5.
- Renal Impairment: In patients with an inadequate response to , the addition of (200-600 mg) produced significant serum urate reductions (16% to 30%) that remained consistent in patients with mild-to-moderate renal insufficiency (CrCl 30 to <90 mL/min) [3]A1b.
Pearl: Treatment selection must prioritize renal and cardiovascular comorbidities, as standard trials often under-represent the high-risk patients seen in primary care [37]B2b[44]B2b. Prophylactic colchicine reduces vaccine-triggered flares by 47% but requires careful monitoring for interactions in the 26% of patients on polypharmacy [37]B2b[38]D5.
| Factor | Adjusted Odds Ratio (AOR) | p-value |
|---|---|---|
| Male Gender | 1.66 | < 0.001 |
| Malay Ethnicity | 1.27 | 0.007 |
| Congestive Heart Failure | 1.64 | 0.037 |
| Prescription of Corticosteroids | 2.83 | < 0.001 |
| Prescription of NSAIDs | 2.76 | < 0.001 |
On the Horizon
- ▸Dotinurad 4 mg/day is superior to febuxostat 40 mg/day in achieving serum urate targets in phase 3 data.
- ▸Methotrexate co-therapy (15 mg/week) significantly improves pegloticase response rates and reduces infusion-related reactions.
- ▸Emerging hURAT1 inhibitors like epaminurad and tigulixostat show high dose-dependent responder rates in early-phase trials.
Emerging therapies for gout focus on novel agents and immunomodulatory strategies to improve urate-lowering therapy (ULT) response rates and reduce treatment burden.
Novel Urate-Lowering Agents
Several selective human urate transporter 1 (hURAT1) inhibitors are in late-stage development. 4 mg/day demonstrated superiority over 40 mg/day in a phase 3 trial, with a responder rate (serum urate ≤6.0 mg/dL) of 73.6% versus 38.1% at week 24 (adjusted difference 35.9% [95% CI 27.4%-44.4%]; P < 0.0001) [52]A1b. Epaminurad, another hURAT1 inhibitor, showed a dose-dependent response at week 4, with 88.89% of patients achieving target urate <0.36 mmol/L at the 9 mg dose compared to 0% for placebo [70]A1b. Additionally, the nonpurine xanthine oxidase inhibitor tigulixostat achieved target urate <5.0 mg/dl in 62.2% of patients at a 200 mg dose [7]A1b.
Immunomodulation and Refractory Gout
For uncontrolled gout, combining with (15 mg/week) significantly increased the month 6 responder rate to 71.0% compared to 38.5% with pegloticase plus placebo (difference 32.3% [95% CI 16.3%, 48.3%]; P < 0.0001) [53]A1b. This combination also reduced infusion reactions from 30.6% to 4.2% [53]A1b. SEL-212, an investigational therapy combining pegadricase with rapamycin-containing nanoparticles (ImmTOR), aims to reduce treatment burden via monthly infusions; it showed comparable efficacy to biweekly pegloticase in a phase 2 -to-head trial [58]A1b.
Adjunctive and Alternative Strategies
In patients with acute decompensated heart failure, the SGLT2 inhibitor may prevent the rise in serum urate typically seen during diuretic therapy, potentially reducing the risk of acute gout episodes [69]A1b. Adjunctive urine alkalization with citrate mixture (3.5 g twice daily) has been associated with fewer gout flares and lower pain scores in men with low urinary pH [61]B2b. While intensive weight loss (mean -15.4 kg) effectively reduces body weight in obese patients, a proof-of-concept trial found no immediate significant reduction in serum urate or gout flares over 16 weeks [65]D5.
Pearl: Novel hURAT1 inhibitors like dotinurad and epaminurad offer potent oral alternatives to xanthine oxidase inhibitors, while methotrexate co-therapy has become a key strategy to double the efficacy of pegloticase in refractory disease [52]A1b[53]A1b[70]A1b.
| Agent | Dose | Target Achievement (sUA) | Comparator | Ref |
|---|---|---|---|---|
| 4 mg daily | 73.6% (≤6.0 mg/dL) | Febuxostat 40 mg (38.1%) | [52]A1b | |
| Epaminurad | 9 mg daily | 88.89% (<0.36 mmol/L) | Placebo (0.0%) | [70]A1b |
| Tigulixostat | 200 mg daily | 62.2% (<5.0 mg/dl) | Placebo (2.9%) | [7]A1b |
| + | 8 mg q2w + 15 mg/wk | 71.0% (<6.0 mg/dL) | Pegloticase + Placebo (38.5%) | [53]A1b |
References
- [1]
Shekelle PG, Newberry SJ, FitzGerald JD et al.. “Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline.” Annals of internal medicine (2016). PMID: 27802478 ↗
L2GUIDELINECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [2]
Stamp L, Horne A, Mihov B et al.. “Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial.” Annals of the rheumatic diseases (2023). PMID: 37652661 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [3]
Perez-Ruiz F, Sundy JS, Miner JN et al.. “Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.” Annals of the rheumatic diseases (2016). PMID: 26742777 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats - [4]
Saag KG, Khanna PP, Keenan RT et al.. “A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33605029 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [5]
Barry A, Helget LN, Androsenko M et al.. “Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38925627 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [6]
Poiley J, Steinberg AS, Choi YJ et al.. “A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout.” Arthritis & rheumatology (Hoboken, N.J.) (2016). PMID: 26989892 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [7]
Terkeltaub R, Lee J, Min J et al.. “Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 36649008 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [8]
Maher D, Reeve E, Hopkins A et al.. “Comparative Risk of Gout Flares When Initiating or Escalating Various Urate-Lowering Therapy: A Systematic Review With Network Meta-Analysis.” Arthritis care & research (2024). PMID: 38303574 ↗
L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [9]
Zeng L, Qasim A, Neogi T et al.. “Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis.” Arthritis care & research (2021). PMID: 32741131 ↗
L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [10]
Qaseem A, Harris RP, Forciea MA et al.. “Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians.” Annals of internal medicine (2016). PMID: 27802508 ↗
L2GUIDELINECited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [11]
Stamp LK, Frampton C, Stewart S et al.. “Relationship Between Gout Flare States and Patient-Reported Outcomes After Allopurinol Initiation.” Arthritis care & research (2025). PMID: 39748204 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [12]
Stamp LK, Horne A, Mihov B et al.. “Colchicine Concentrations and Relationship With Colchicine Efficacy and Adverse Events: Post Hoc Analysis of a Randomized Clinical Trial of Colchicine for Gout Flare Prophylaxis.” Arthritis care & research (2025). PMID: 40223442 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [13]
Stamp LK, Horne A, Mihov B et al.. “Predicting Gout Flares in People Starting Allopurinol Using the Start-Low Go-Slow Dose Escalation Strategy.” Arthritis care & research (2024). PMID: 38766703 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [14]
Pryymachenko Y, Wilson R, Dalbeth N et al.. “Cost-Effectiveness of Low-Dose Colchicine Prophylaxis When Starting Allopurinol Using the "Start-Low Go-Slow" Approach for Gout: Evidence From a Noninferiority Randomized Double-Blind Placebo-Controlled Trial.” Arthritis care & research (2025). PMID: 40827007 ↗
L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [15]
Roddy E, Clarkson K, Blagojevic-Bucknall M et al.. “Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care.” Annals of the rheumatic diseases (2019). PMID: 31666237 ↗
L2TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [16]
Russell MD, Clarke BD, Roddy E et al.. “Improving outcomes for patients hospitalized with gout: a systematic review.” Rheumatology (Oxford, England) (2021). PMID: 34247233 ↗
L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [17]
Banerjee M, Pal R, Maisnam I et al.. “Serum uric acid lowering and effects of sodium-glucose cotransporter-2 inhibitors on gout: A meta-analysis and meta-regression of randomized controlled trials.” Diabetes, obesity & metabolism (2023). PMID: 37334516 ↗
L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [18]
Yu J, Lu H, Zhou J et al.. “Oral prednisolone versus non-steroidal anti-inflammatory drugs in the treatment of acute gout: a meta-analysis of randomized controlled trials.” Inflammopharmacology (2018). PMID: 29357007 ↗
L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [19]
Billy CA, Lim RT, Ruospo M et al.. “Corticosteroid or Nonsteroidal Antiinflammatory Drugs for the Treatment of Acute Gout: A Systematic Review of Randomized Controlled Trials.” The Journal of rheumatology (2017). PMID: 28765243 ↗
L1SR_MA_RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [20]
Scheepers LEJM, Burden AM, Arts ICW et al.. “Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).” Rheumatology (Oxford, England) (2018). PMID: 29893941 ↗
L3COHORTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats - [21]
Kim HW, Joo YS, Yun HR et al.. “Colchicine use and the risk of CKD progression: a multicentre nested case-control study.” Rheumatology (Oxford, England) (2022). PMID: 35139160 ↗
L3CASE_CONTROLCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [22]
Robinson PC, Dalbeth N, Donovan P. “Cost-Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol.” Arthritis care & research (2021). PMID: 32558298 ↗
L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [23]
Kwok TSH, Kuriya B, Hawker G et al.. “Adherence and Treat-to-Target Benchmarks in Older Adults With Gout Initiating Urate-Lowering Therapy in Ontario, Canada: A Population-Based Study.” Arthritis care & research (2024). PMID: 38831665 ↗
L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [24]
Zhou X, Peng S, Hu L et al.. “Meridian-Sinew Release Therapy as an adjunctive treatment for gouty arthritis: a systematic review and meta-analysis.” Journal of orthopaedic surgery and research (2025). PMID: 40826358 ↗
L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon - [25]
Butt JH, Docherty KF, Claggett BL et al.. “Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER.” JAMA cardiology (2023). PMID: 36811901 ↗
L2SR_OBSCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [26]
Parperis K, Papachristodoulou E, Kakoullis L et al.. “Management of calcium pyrophosphate crystal deposition disease: A systematic review.” Seminars in arthritis and rheumatism (2020). PMID: 33360232 ↗
L2SR_OBSCited in: Bottom Line, Current Evidence and Standard - [27]
Janssen CA, Oude Voshaar MAH, Vonkeman HE et al.. “Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial.” Rheumatology (Oxford, England) (2019). PMID: 30602035 ↗
L5OTHERCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard - [28]
Zhang W, Doherty M, Bardin T et al.. “EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).” Annals of the rheumatic diseases (2006). PMID: 16707532 ↗
L2GUIDELINECited in: Background: Evolution of Treatment - [29]
Schlesinger N, Alten RE, Bardin T et al.. “Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.” Annals of the rheumatic diseases (2012). PMID: 22586173 ↗
L1RCTCited in: Background: Evolution of Treatment - [30]
Schlesinger N, Mysler E, Lin HY et al.. “Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.” Annals of the rheumatic diseases (2011). PMID: 21540198 ↗
L1RCTCited in: Background: Evolution of Treatment - [31]
Janssens HJ, Janssen M, van de Lisdonk EH et al.. “Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial.” Lancet (London, England) (2008). PMID: 18514729 ↗
L1RCTCited in: Background: Evolution of Treatment - [32]
Sutaria S, Katbamna R, Underwood M. “Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review.” Rheumatology (Oxford, England) (2006). PMID: 16632483 ↗
L2SR_OBSCited in: Background: Evolution of Treatment - [33]
Singh JA, Hodges JS, Asch SM. “Opportunities for improving medication use and monitoring in gout.” Annals of the rheumatic diseases (2008). PMID: 18701554 ↗
L5OTHERCited in: Background: Evolution of Treatment - [34]
Janssens HJ, Lucassen PL, Van de Laar FA et al.. “Systemic corticosteroids for acute gout.” The Cochrane database of systematic reviews (2008). PMID: 18425920 ↗
L2SR_OBSCited in: Background: Evolution of Treatment - [35]
Perez-Ruiz F. “Treating to target: a strategy to cure gout.” Rheumatology (Oxford, England) (2009). PMID: 19447780 ↗
L5REVIEW_NARRATIVECited in: Background: Evolution of Treatment - [36]
Khanna PP, Perez-Ruiz F, Maranian P et al.. “Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout.” Rheumatology (Oxford, England) (2010). PMID: 21147824 ↗
L5OTHERCited in: Background: Evolution of Treatment - [37]
Bajpai R, Partington R, Muller S et al.. “Prognostic factors for colchicine prophylaxis-related adverse events when initiating allopurinol for gout: retrospective cohort study.” Rheumatology (Oxford, England) (2025). PMID: 38636489 ↗
L3COHORTCited in: Applicability and Caveats - [38]
Lu J, He Y, Terkeltaub R et al.. “Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination.” Annals of the rheumatic diseases (2022). PMID: 35277390 ↗
L5OTHERCited in: Applicability and Caveats - [39]
McKenzie BJ, Wechalekar MD, Johnston RV et al.. “Colchicine for acute gout.” The Cochrane database of systematic reviews (2021). PMID: 34438469 ↗
L2SR_OBSCited in: Applicability and Caveats - [40]
Kim HW, Kang M, Lim H et al.. “Association between colchicine use and adverse cardiovascular events in patients with gout: a nationwide nested case-control study.” Rheumatology (Oxford, England) (2025). PMID: 39392785 ↗
L3CASE_CONTROLCited in: Applicability and Caveats - [41]
Bowen-Davies Z, Muller S, Mallen CD et al.. “Gout Severity, Socioeconomic Status, and Work Absence: A Cross-Sectional Study in Primary Care.” Arthritis care & research (2018). PMID: 29579363 ↗
L5OTHERCited in: Applicability and Caveats - [42]
Kwok TSH, Kuriya B, Hawker G et al.. “Serum Urate Monitoring Among Older Adults With Gout: Initiating Urate-Lowering Therapy in Ontario, Canada.” Arthritis care & research (2023). PMID: 37248652 ↗
L5OTHERCited in: Applicability and Caveats - [43]
Toprover M, Shah B, Oh C et al.. “Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study.” Arthritis research & therapy (2020). PMID: 32653044 ↗
L5OTHERCited in: Applicability and Caveats - [44]
Liu J, Gamble GD, Dalbeth N. “Are participants in gout medication registration clinical trials representative of people with gout in the general population?” Seminars in arthritis and rheumatism (2025). PMID: 39919487 ↗
L2TRIAL_NONRANDOMCited in: Applicability and Caveats - [45]
Richter A, Truthmann J, Hummers E et al.. “Prednisolone Versus Colchicine for Acute Gout in Primary Care: statistical analysis plan for the pragmatic, multicenter, randomized, and double-blinded COPAGO non-inferiority trial.” Trials (2024). PMID: 38570873 ↗
L1RCTCited in: Applicability and Caveats - [46]
Pascart T, Lioté F. “Gout: state of the art after a decade of developments.” Rheumatology (Oxford, England) (2019). PMID: 29547895 ↗
L5REVIEW_NARRATIVECited in: Applicability and Caveats - [47]
Latourte A, Pascart T, Flipo RM et al.. “2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares.” Joint bone spine (2020). PMID: 32422339 ↗
L5OTHERCited in: Applicability and Caveats - [48]
Oka P, Chong WM, Ng DX et al.. “Epidemiology and risk factors associated with gout control among adult Asians: a real-world retrospective cohort study.” Frontiers in medicine (2023). PMID: 37746085 ↗
L3COHORTCited in: Applicability and Caveats - [49]
Chuang JP, Lee JC, Leu TH et al.. “Association of gout and colorectal cancer in Taiwan: a nationwide population-based cohort study.” BMJ open (2019). PMID: 31601586 ↗
L3COHORTCited in: Applicability and Caveats - [50]
Truthmann J, Freyer Martins Pereira J, Richter A et al.. “Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel group design.” Trials (2023). PMID: 37798801 ↗
L2TRIAL_NONRANDOMCited in: Applicability and Caveats - [51]
Walsh CP, Prior JA, Chandratre P et al.. “Illness perceptions of gout patients and the use of allopurinol in primary care: baseline findings from a prospective cohort study.” BMC musculoskeletal disorders (2016). PMID: 27639692 ↗
L3COHORTCited in: Applicability and Caveats - [52]
Sun J, Wang Y, Cheng Y et al.. “Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40417858 ↗
L1RCTCited in: On the Horizon - [53]
Botson JK, Saag K, Peterson J et al.. “A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 36099211 ↗
L1RCTCited in: On the Horizon - [54]
Helget LN, O'Dell JR, Newcomb JA et al.. “Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37842953 ↗
L1RCTCited in: On the Horizon - [55]
Barry A, England BR, Sayles H et al.. “Improvements in Health-Related Quality of Life With Treat-to-Target Urate-Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial.” Arthritis care & research (2025). PMID: 40771143 ↗
L1RCTCited in: On the Horizon - [56]
Tabi-Amponsah AD, Stewart S, Gamble G et al.. “Time Trends and Predictors of Gout Remission Over 6 Years.” Arthritis care & research (2025). PMID: 40528737 ↗
L1RCTCited in: On the Horizon - [57]
Murdoch R, Mihov B, Horne AM et al.. “Impact of Television Depictions of Gout on Perceptions of Illness: A Randomized Controlled Trial.” Arthritis care & research (2023). PMID: 37038965 ↗
L1RCTCited in: On the Horizon - [58]
Baraf HSB, Khanna PP, Kivitz AJ et al.. “The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.” Rheumatology (Oxford, England) (2024). PMID: 37449908 ↗
L1RCTCited in: On the Horizon - [59]
Selvadurai D, Coleshill MJ, Day RO et al.. “Patient factors and health outcomes associated with illness perceptions in people with gout.” Rheumatology (Oxford, England) (2024). PMID: 37769230 ↗
L1RCTCited in: On the Horizon - [60]
Cao C, Gamble G, Horne A et al.. “The Tophus Impact Questionnaire (TIQ-20): responsiveness to change during urate-lowering therapy.” Rheumatology (Oxford, England) (2024). PMID: 37688559 ↗
L1RCTCited in: On the Horizon - [61]
Wang C, Guo K, Dalbeth N et al.. “Impact of adding urine alkalization therapy to xanthine oxidase inhibitor in gout management: a prospective cohort study.” Rheumatology (Oxford, England) (2025). PMID: 39932882 ↗
L2TRIAL_NONRANDOMCited in: On the Horizon - [62]
Cheng Z, Xu X, Qi H et al.. “Obesity reduces the urate-lowering efficacy among patients with primary gout: a prospective cohort study.” Rheumatology (Oxford, England) (2025). PMID: 39928353 ↗
L2TRIAL_NONRANDOMCited in: On the Horizon - [63]
Troum OM, Duong M, Obermeyer K et al.. “Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase.” Rheumatology (Oxford, England) (2025). PMID: 39792028 ↗
L2TRIAL_NONRANDOMCited in: On the Horizon - [64]
Hammer HB, Karoliussen L, Terslev L et al.. “Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study.” Annals of the rheumatic diseases (2025). PMID: 41271521 ↗
L5OTHERCited in: On the Horizon - [65]
Christensen R, Zobbe K, Nielsen SM et al.. “Weight Loss for Patients With Gout and Concomitant Obesity: A Proof-of-Concept Randomized Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38169151 ↗
L5OTHERCited in: On the Horizon - [66]
Rasmussen C, Larsen JW, Christensen HM et al.. “Optimising gout treatment: insights from a nurse-led cohort study.” RMD open (2024). PMID: 38663881 ↗
L3COHORTCited in: On the Horizon - [67]
Zhao X, Fan Y, Sun J et al.. “Efficacy and safety of Chinese herbal compound in the treatment of acute gouty arthritis: A systematic review and meta-analysis of randomized controlled trials.” International immunopharmacology (2025). PMID: 39923577 ↗
L1SR_MA_RCTCited in: On the Horizon - [68]
Cai Z, Lv Y, Liu Y et al.. “Quantitative evaluation of clinical efficacy and safety of uric acid-lowering drugs: A modeling analysis of literature aggregate data.” Seminars in arthritis and rheumatism (2025). PMID: 40780110 ↗
L2SR_OBSCited in: On the Horizon - [69]
Bogoviku J, Nguyen TD, Westphal JG et al.. “Effects of empagliflozin on uric acid levels during acute heart failure recompensation: A sub-analysis of the EMPAG-HF trial (Effects of Empagliflozin on Diuresis and Renal Function in Patients with Acute Decompensated Heart Failure).” European journal of heart failure (2025). PMID: 40631522 ↗
L1RCTCited in: On the Horizon - [70]
Jun JB, Lee HS, Kim SH et al.. “Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study.” Arthritis research & therapy (2025). PMID: 40420308 ↗
L1RCTCited in: On the Horizon - [71]
Uhlig T, Karoliussen LF, Sexton J et al.. “Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study.” Rheumatology (Oxford, England) (2025). PMID: 39292608 ↗
L5OTHERCited in: On the Horizon - [72]
Bartsch V, Standfest K, Hueber A. “[Gout : From the diagnosis to guideline-based treatment].” Zeitschrift fur Gerontologie und Geriatrie (2025). PMID: 39998560 ↗
L5OTHERCited in: On the Horizon